ID   TUR
AC   CVCL_1775
SY   TPA-U937-resistant
DR   CLO; CLO_0009447
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-3610
DR   ATCC; CRL-2367
DR   BioSample; SAMN03471833
DR   cancercelllines; CVCL_1775
DR   Cell_Model_Passport; SIDM01205
DR   ChEMBL-Cells; CHEMBL3308519
DR   ChEMBL-Targets; CHEMBL2366218
DR   Cosmic; 683549
DR   Cosmic; 909773
DR   Cosmic-CLP; 909773
DR   DepMap; ACH-002314
DR   EGA; EGAS00001000978
DR   GDSC; 909773
DR   GEO; GSM186464
DR   GEO; GSM1670551
DR   IARC_TP53; 27263
DR   LINCS_LDP; LCL-2063
DR   PharmacoDB; TUR_1613_2019
DR   PRIDE; PXD030304
DR   Progenetix; CVCL_1775
DR   PubChem_Cell_line; CVCL_1775
DR   Wikidata; Q54973376
RX   PubMed=7720732;
RX   PubMed=8398907;
RX   PubMed=20164919;
RX   PubMed=27397505;
RX   PubMed=30894373;
RX   PubMed=35839778;
WW   https://web.archive.org/web/20201109215324/www.infarktforschung.de/macrophages_cell_lines.html
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Population: Caucasian.
CC   Microsatellite instability: Instable (MSI-high) (Sanger).
CC   Sequence variation: Gene fusion; HGNC; 16063; MLLT10 + HGNC; 15514; PICALM; Name(s)=PICALM-MLLT10, CALM-AF10 (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Gly129fs*51 (c.387_388insCGCC); Zygosity=Hemizygous (DepMap).
CC   Sequence variation: Mutation; HGNC; 9644; PTPN11; Simple; p.Gly60Arg (c.178G>C); ClinVar=VCV000372590; Zygosity=Heterozygous (DepMap).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.559+1G>A (p.Val173Trpfs*59); ClinVar=VCV000428908; Zygosity=Homozygous; Note=Splice donor mutation (DepMap).
CC   Sequence variation: Mutation; HGNC; 12796; WT1; Simple; p.Arg301Ter (c.901C>T) (p.Arg352Ter, c.1054C>T) (p.Arg374Ter, c.1120C>T); ClinVar=VCV000449416; Zygosity=Heterozygous (DepMap).
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Genome ancestry: African=0%; Native American=0.04%; East Asian, North=0.5%; East Asian, South=0%; South Asian=1.33%; European, North=75.18%; European, South=22.94% (PubMed=30894373).
CC   Derived from site: In situ; Pleural effusion; UBERON=UBERON_0000175.
ST   Source(s): ATCC; Cosmic-CLP
ST   Amelogenin: X
ST   CSF1PO: 12
ST   D13S317: 10,12
ST   D16S539: 12
ST   D5S818: 12
ST   D7S820: 9,11
ST   TH01: 6,9.3
ST   TPOX: 8,11
ST   vWA: 14,16
DI   NCIt; C8263; Adult acute monocytic leukemia
DI   ORDO; Orphanet_514; Acute monoblastic/monocytic leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0007 ! U-937
SX   Male
AG   37Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 36
//
RX   PubMed=7720732;
RA   Hass R., Meinhardt G., Hadam M., Bartels H.;
RT   "Characterization of human TUR leukemia cells: continued cell cycle
RT   progression in the presence of phorbol ester is associated with
RT   resistance to apoptosis.";
RL   Eur. J. Cell Biol. 65:408-416(1994).
//
RX   PubMed=8398907;
RA   Hass R., Hirano M., Kharbanda S., Rubin E.H., Meinhardt G., Kufe D.W.;
RT   "Resistance to phorbol ester-induced differentiation of a U-937
RT   myeloid leukemia cell variant with a signaling defect upstream to Raf-1
RT   kinase.";
RL   Cell Growth Differ. 4:657-663(1993).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//